Roche (OTCQX:RHHBY) (OTCQX:RHHBF) will finalize the acquisition of Poseida Therapeutics (NASDAQ:PSTX), a biopharmaceutical company specializing in complex immune cell therapies to treat several types ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market. Learn more on RHHBY stock here.

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX – Get Free Report) hit a new 52-week high on Tuesday .The stock traded as high as $9.60 and last traded at $9.57, with a volume of 470167 shares ...

Poseida Therapeutics Inc (PSTX) stock saw a modest uptick, ending the day at $9.56 which represents a slight increase of $0.04 or 0.42% from the prior close of $9.52. The stock opened at $9.52 and ...

In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report), ...

Recent health news includes Donald Trump's consideration of an executive order on gas stoves, Roche's acquisition of Poseida, and GSK and Pfizer's RSV vaccine warnings. The WHO notes low bird flu risk ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Blue Giant Acquisition Corp. has accepted for payment all shares validly tendered and not validly withdrawn ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) will finalize the acquisition of Poseida Therapeutics (NASDAQ:PSTX), a biopharmaceutical company specializing in complex immune cell therapies to treat several ...

Poseida Therapeutics has completed a merger where it has become a wholly owned subsidiary of a Parent company. As a result of the merger, the company has delisted its shares from Nasdaq and plans ...